F. L. Meyskens - Concepedia

Author

F. L. Meyskens

Also Known As

F L Meyskens, F Meyskens, F. L. MEYSKENS, F. L. Meyskens, F. L. Meyskens,, F. MEYSKENS, F. Meyskens, F.L Meyskens Jr, F.L. Meyskens, Frank L. Meyskens

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University of Arizona University of California, Irvine

About

F. L. Meyskens is an author at University of Arizona specializing in medicine, cancer research, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	927
2	Health Sciences	2	2	67
3	Natural Sciences	1	1	339
4	Biochemistry	1	1	339
5	Biomolecular Engineering	1	1	339

F. L. Meyskens

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Dennis J. Ahnen, Polly Feigl, G. Quan, PubMed Tumor BiologyKi-ras MutationCancer EpidemiologyMedicineP53 Expression	1998	349
Development of difluoromethylornithine (DFMO) as a chemoprevention agent. F. L. Meyskens, Eugene W. Gerner PubMed Medicinal ChemistryChemoprevention StrategyBiochemistryOncogenic AgentMedicine	1999	339
Enhancement of Regression of Cervical Intraepithelial Neoplasia II (Moderate Dysplasia) With Topically Applied All- trans -Retinoic Acid: a Randomized Trial F. L. Meyskens, Earl A. Surwit, Thomas E. Moon, JNCI Journal of the National Cancer Institute	1994	268
Phase I-II study of 13-cis-retinoic acid in myelodysplastic syndrome. Bernard R. Greenberg, B G M Durie, Tammy Barnett, PubMed Hematological MalignancyThrombosisMedicineAplastic AnemiaPhase I-ii Study	1985	52
Phase I trial of retinol in cancer patients. Gary E. Goodman, D S Alberts, D L Earnst, Journal of Clinical Oncology Chemoprevention StrategyCancer ManagementPharmacotherapyCancer PatientsDermatology	1983	43
-Difluoromethylornithine and Polyamine Levels in the Human Prostate: Results of a Phase IIa Trial Anne R. Simoneau, Eugene W. Gerner, Michael C. Phung, JNCI Journal of the National Cancer Institute Molecular PharmacologyPolyamine LevelsUrologyHuman ProstateGenitourinary Cancer	2001	42
Dexamethasone, Prostaglandin A, and Retinoic Acid Modulation of Murine and Human Melanoma Cells Grown in Soft Agar<xref ref-type="fn" rid="FN2">2</xref><xref ref-type="fn" rid="FN3">3</xref> Marvin D. Bregman, E Peters, D Sander, JNCI Journal of the National Cancer Institute Prostaglandin ACell ProliferationRetinoic Acid ModulationDermatologyCellular Physiology	1983	34
Dose-Related α-Difluoromethylornithine Ototoxicity Marilyn K. Croghan, Mikel Aickin, F. L. Meyskens American Journal of Clinical Oncology	1991	33
Ornithine Decarboxylase-1 Polymorphism, Chemoprevention With Eflornithine and Sulindac, and Outcomes Among Colorectal Adenoma Patients Jason A. Zell, C. E. McLaren, Wen‐Pin Chen, JNCI Journal of the National Cancer Institute Odc1 GenotypeGastroenterologyPathologyPharmacotherapyLogistic Analysis	2010	33
Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial Carol M. Moinpour, Michelle Savage, Andrea B. Troxel, The Journal of Urology Quality Of LifeCancer ManagementUrogenital RadiologyOncologyGenitourinary Cancer	1999	24

Page 1